pharmaphorum
JANUARY 10, 2023
Other IgG proteases are being developed to tackle the issue of pre-existing immunity against AAV, but according to Selecta chief executive Carsten Brun these tend to be derived from common human pathogens – which means they themselves can be the target of existing antibodies.
Pharmaceutical Technology
MAY 19, 2023
The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 4, 2023
According to Research and Markets 8 , the market for bispecific antibodies for cancer is forecasted to grow by $400 million during 2022-2027, due to the increasing prevalence of cancer worldwide. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity.
pharmaphorum
JANUARY 17, 2023
Its vocal biomarkers are already being used to gauge the effect of drug treatments for dementia, including in the phase 2 TAURIEL trial of Roche/AC Immune’s’s tau protein-targeted antibody semorinemab. million) to its top-line in 2023 with “considerable growth” next year.
The Checkup by Singlecare
NOVEMBER 6, 2023
According to the FDA announcement, the most serious side effect of Wezlana is infection because the prescription affects your immune response. Crohn’s disease What are the possible side effects of Wezlana?
Roots Analysis
OCTOBER 4, 2023
They are designed to recognize and bind to two specific molecules, such as a tumor cell and an immune cell, or two different parts of the same molecule. Bispecific antibodies are a type of antibody that can bind to two different targets at the same time. during the period 2023-2035. during the period 2023-2035.
European Pharmaceutical Review
FEBRUARY 22, 2023
1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027.
Expert insights. Personalized for you.
119 
Let's personalize your content